KNSTRN promotes tumorigenesis and gemcitabine resistance by activating AKT in bladder cancer

KNSTRN is a component of the mitotic spindle, which was rarely investigated in tumorigenesis. AKT plays an essential role in tumorigenesis by modulating the phosphorylation of various substrates. The activation of AKT is regulated by PTEN and PIP 3 . Here, we prove KNSTRN is positively correlated wi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncogene 2021-03, Vol.40 (9), p.1595-1608
Hauptverfasser: Xiong, Yaoyi, Ju, Lingao, Yuan, Lushun, Chen, Liang, Wang, Gang, Xu, Huimin, Peng, Tianchen, Luo, Yongwen, Xiao, Yu, Wang, Xinghuan
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:KNSTRN is a component of the mitotic spindle, which was rarely investigated in tumorigenesis. AKT plays an essential role in tumorigenesis by modulating the phosphorylation of various substrates. The activation of AKT is regulated by PTEN and PIP 3 . Here, we prove KNSTRN is positively correlated with malignancy of bladder cancer and KNSTRN activates AKT phosphorylation at Thr308 and Ser473. More importantly, our study reveals that both KNSTRN and PTEN interact with PH domain of AKT at cell membrane. The amount of KNSTRN interacted with AKT is negatively related to PTEN. Furthermore, PIP 3 pull-down assay proves that KNSTRN promoted AKT movement to PIP 3 . These data suggest KNSTRN may activate AKT phosphorylation by promoting AKT movement to PIP 3 and alleviating PTEN suppression. Based on the activation of AKT phosphorylation, our study demonstrates that KNSTRN promotes bladder cancer metastasis and gemcitabine resistance in vitro and in vivo. Meanwhile, the effect of KNSTRN on tumorigenesis and gemcitabine resistance could be restored by AKT specific inhibitor MK2206 or AKT overexpression. In conclusion, we identify an oncogene KNSTRN that promotes tumorigenesis and gemcitabine resistance by activating AKT phosphorylation and may serve as a therapeutic target in bladder cancer.
ISSN:0950-9232
1476-5594
DOI:10.1038/s41388-020-01634-z